Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) announced that the RAY1225 injection, an innovative polypeptide drug independently developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as “Zhongsheng Ruichuang”), the holding subsidiary of the company, recently obtained top-line analysis data from phase I clinical trials. The research results initially showed that RAY1225 injection had good safety tolerability and excellent pharmacokinetic characteristics. The test results were ideal and achieved the expected goals.

Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) announced that the RAY1225 injection, an innovative polypeptide drug independently developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as “Zhongsheng Ruichuang”), the holding subsidiary of the company, recently obtained top-line analysis data from phase I clinical trials. The research results initially showed that RAY1225 injection had good safety tolerability and excellent pharmacokinetic characteristics. The test results were ideal and achieved the expected goals.